<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01836523</url>
  </required_header>
  <id_info>
    <org_study_id>NN9211-3919</org_study_id>
    <secondary_id>2012-003580-21</secondary_id>
    <secondary_id>U1111-1133-0590</secondary_id>
    <nct_id>NCT01836523</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes</brief_title>
  <acronym>ADJUNCT ONEâ„¢</acronym>
  <official_title>The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted globally. The aim of the trial is to confirm the efficacy and safety
      of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes. The total
      trial duration per subject is approximately 58 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in HbA1c (Glycosylated Haemoglobin)</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from baseline in HbA1c at week 52. Missing values were handled by using a mixed model for repeated measurements (MMRM).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Body Weight</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from baseline in body weight at week 52. Missing values were handled by using a MMRM.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Total Daily Insulin Dose</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from baseline in total daily insulin dose at week 52. Change from baseline was represented in terms of ratio to baseline for insulin dose i.e. Total daily insulin dose at week 52/total daily insulin dose at baseline. Missing values were handled by using a MMRM.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Treatment-emergent Symptomatic Hypoglycaemic Episodes</measure>
    <time_frame>Weeks 0-52</time_frame>
    <description>This is a confirmatory secondary endpoint. Symptomatic hypoglycaemic episodes were defined as: 1) Severe according to the American Diabetes Association (ADA) classification: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. OR 2) Self-monitoring of plasma glucose value of &lt;3.1 mmol/L, with symptoms consistent with hypoglycaemia. A treatment emergent episode is defined as an episode with onset date (or increase in severity) on or after first day of exposure to randomised treatment and up to last dose + 7 days.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">1398</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Liraglutide 0.6 mg + insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide 1.2 mg + insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide 1.8 mg + insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide placebo 0.6 mg + insulin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide placebo 1.2 mg + insulin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide placebo 1.8 mg + insulin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.</description>
    <arm_group_label>Liraglutide 0.6 mg + insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.</description>
    <arm_group_label>Liraglutide placebo 0.6 mg + insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.</description>
    <arm_group_label>Liraglutide 1.2 mg + insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.</description>
    <arm_group_label>Liraglutide placebo 1.2 mg + insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.</description>
    <arm_group_label>Liraglutide 1.8 mg + insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.</description>
    <arm_group_label>Liraglutide placebo 1.8 mg + insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - Informed consent obtained

          -  - Type 1 diabetes mellitus for 12 months or longer

          -  - Basal bolus or CSII (Continuous Subcutaneous Insulin Infusion, insulin pump)
             treatment for 6 months or longer

          -  - Stable insulin treatment for the last 3 months prior to Screening, as judged and
             documented by the investigator

          -  - HbA1c 7.0-10% (Diabetes Control and Complications Trial (DCCT)), both inclusive,
             (corresponding to 53-86 mmol/mol (International Federation of Clinical Chemistry
             (IFCC))

          -  - Ability and willingness to comply with all protocol procedures e.g. correct handling
             of trial product, complete trial related questionnaires, diaries, self-monitoring of
             plasma glucose, self titration of insulin and attend all scheduled visits

        Exclusion Criteria:

          -  - Prior use of glucagon-like peptide-1 (GLP-1) receptor agonist or dipeptidyl
             peptidase IV (DPP-4) inhibitors

          -  - Use of any medication, which in the investigator's opinion could interfere with the
             glycaemic control or affect the subject's safety.Premix insulin is not allowed

          -  - Known proliferative retinopathy or maculopathy requiring acute treatment

          -  - Severe neuropathy, in particular autonomic neuropathy, i.e. gastroparesis, as judged
             by the investigator

          -  - Uncontrolled/ untreated blood pressure at screening above 160 mmHg for systolic or
             above 100 mmHg for diastolic

          -  - History of acute or chronic pancreatitis

          -  - Screening calcitonin value equal to or above 50 ng/L

          -  - Personal or family history of medullary thyroid carcinoma or Multiple Endocrine
             Neoplasia type 2 (MEN2)

          -  - Diagnosis of malignant neoplasm in the previous 5 years (except basal cell skin
             cancer or squamous cell skin cancer)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Monterey</city>
        <state>California</state>
        <zip>93940</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>San Mateo</city>
        <state>California</state>
        <zip>94401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>San Ramon</city>
        <state>California</state>
        <zip>94583</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <zip>33312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33619</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308-2253</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404-7596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <zip>51501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Metarie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>St. Charles</city>
        <state>Missouri</state>
        <zip>63303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110-1020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>St. Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224-2215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Upper Darby</city>
        <state>Pennsylvania</state>
        <zip>19082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <zip>29485</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404-1192</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119-3821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bennington</city>
        <state>Vermont</state>
        <zip>05201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Federal Way</city>
        <state>Washington</state>
        <zip>98003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Caba</city>
        <zip>C1118AAT</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Caba</city>
        <zip>C1440AAD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <zip>1405</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>CÃ³rdoba</city>
        <zip>X5016KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mendoza</city>
        <zip>5500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>MorÃ³n</city>
        <zip>B1708IFF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Broadmeadow</city>
        <state>New South Wales</state>
        <zip>2292</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Elizabeth Vale</city>
        <state>South Australia</state>
        <zip>5112</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Keswick</city>
        <state>South Australia</state>
        <zip>5035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Arlon</city>
        <zip>6700</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>LiÃ¨ge</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 7L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6M 1M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Thornhill</city>
        <state>Ontario</state>
        <zip>L4J 8L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1R7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1G 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00250</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pori</city>
        <zip>28500</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>SeinÃ¤joki</city>
        <zip>60220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>SeinÃ¤joki</city>
        <zip>60510</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Turku</city>
        <zip>FI-20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Corbeil Essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>DIJON cedex</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Le Creusot</city>
        <zip>71200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Narbonne</city>
        <zip>11108</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pointe Ã  Pitre</city>
        <zip>97159</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Venissieux</city>
        <zip>69200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Eisenach</city>
        <zip>99817</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Essen</city>
        <zip>45219</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>21073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22607</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>HohenmÃ¶lsen</city>
        <zip>06679</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Marburg</city>
        <zip>35039</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>MÃ¼nster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pohlheim</city>
        <zip>35415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rehlingen-Siersburg</city>
        <zip>66780</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>St. Ingbert</city>
        <zip>66386</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dublin 9</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dublin</city>
        <zip>DUBLIN 15</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dublin</city>
        <zip>DUBLIN 4</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dublin</city>
        <zip>DUBLIN 7</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>93106</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49202</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rishon Le Zion</city>
        <zip>75650</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Den Haag</city>
        <zip>2512 VA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hoogeveen</city>
        <zip>7909 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3011 TA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Venlo</city>
        <zip>5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gjettum</city>
        <zip>1346</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hamar</city>
        <zip>2318</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kongsvinger</city>
        <zip>2226</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Stavanger</city>
        <zip>4011</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-044</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pulawy</city>
        <zip>24-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>00-911</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>03-242</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kazan</city>
        <zip>420073</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Penza</city>
        <zip>440026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saratov</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Volgograd</city>
        <zip>400138</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>GÃ¶teborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>MalmÃ¶</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>112 81</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kharkov</city>
        <zip>61058</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kharkov</city>
        <zip>61070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kiev</city>
        <zip>04114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Poltava</city>
        <zip>36011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Zhytomir</city>
        <zip>10002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Blackburn</city>
        <zip>BB2 3HH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Durham</city>
        <zip>DH11 5TW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Edgbaston, Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Middlesbrough</city>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Southall</city>
        <zip>UB1 3HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>St Helens</city>
        <zip>WA9 3DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Stevenage</city>
        <zip>SG1 4AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Sweden</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Mathieu C, Zinman B, Hemmingsson JU, Woo V, Colman P, Christiansen E, Linder M, Bode B; ADJUNCT ONE Investigators. Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care. 2016 Oct;39(10):1702-10. doi: 10.2337/dc16-0691. Epub 2016 Aug 9.</citation>
    <PMID>27506222</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2013</study_first_submitted>
  <study_first_submitted_qc>April 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2013</study_first_posted>
  <results_first_submitted>May 23, 2016</results_first_submitted>
  <results_first_submitted_qc>January 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 6, 2017</results_first_posted>
  <last_update_submitted>January 16, 2017</last_update_submitted>
  <last_update_submitted_qc>January 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was conducted at 177 sites in 17 countries: Argentina: 6, Australia: 5, Belgium: 4, Canada: 14, Germany: 8, Finland: 6, France: 13, United Kingdom: 10, Ireland: 5, Israel: 6, Netherlands: 6, Norway: 5, Poland: 5, Russia: 5, Sweden: 4, Ukraine: 5, United States: 70</recruitment_details>
      <pre_assignment_details>Eligible subjects were randomised in a 3:3:3:1:1:1 manner to receive liraglutide (0.6 mg, 1.2 mg or 1.8 mg) or placebo (0.1 mL, 0.2 mL or 0.3 mL), both adjunct to insulin treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Liraglutide 0.6 mg</title>
          <description>Subjects received liraglutide 0.6 mg once daily (OD) subcutaneously for 52 weeks in addition to their pre-trial insulin treatment.</description>
        </group>
        <group group_id="P2">
          <title>Liraglutide 1.2 mg</title>
          <description>Subjects received liraglutide 0.6 mg OD subcutaneously for 2 weeks followed by 1.2 mg OD subcutaneously up to week 52 in addition to their pre-trial insulin treatment.</description>
        </group>
        <group group_id="P3">
          <title>Liraglutide 1.8 mg</title>
          <description>Liraglutide 0.6 mg OD subcutaneously for 2 weeks followed by 1.2 mg OD subcutaneously for 2 weeks (weeks 2-4) followed by 1.8 mg OD subcutaneously up to week 52 in addition to their pre-trial insulin treatment.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Subjects received placebo (matched to liraglutide 0.6, 1.2 and 1.8 mg) OD subcutaneously as an add-on to their pre-trial insulin treatment. Placebo 0.1 mL (placebo matched to liraglutide 0.6 mg): Subjects received 0.1 mL liraglutide placebo for 52 weeks. Placebo 0.2 mL (placebo matched to liraglutide 1.2 mg): Subjects received 0.1 mL for 2 weeks followed by 0.2 mL up to week 52. Placebo 0.3 mL (placebo matched to liraglutide 1.8 mg): Subjects received 0.1 mL for 2 weeks followed by 0.2 mL for next 2 weeks and 0.3 mL up to week 52. All the 3 placebo doses were pooled for data analysis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="351"/>
                <participants group_id="P2" count="350"/>
                <participants group_id="P3" count="349"/>
                <participants group_id="P4" count="348"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Exposed</title>
              <participants_list>
                <participants group_id="P1" count="350"/>
                <participants group_id="P2" count="348"/>
                <participants group_id="P3" count="347"/>
                <participants group_id="P4" count="348"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="300"/>
                <participants group_id="P2" count="265"/>
                <participants group_id="P3" count="258"/>
                <participants group_id="P4" count="274"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="85"/>
                <participants group_id="P3" count="91"/>
                <participants group_id="P4" count="74"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="49"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met Withdrawal Criteria</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unclassified</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS) included all randomised subjects who received at least one dose and had any post-randomisation data. Five subjects, who started the study, were excluded because of no exposure to study drug and 4 subjects were excluded because of non-availability of post-baseline data.</population>
      <group_list>
        <group group_id="B1">
          <title>Liraglutide 0.6 mg</title>
          <description>Subjects received liraglutide 0.6 mg once daily (OD) subcutaneously for 52 weeks in addition to their pre-trial insulin treatment.</description>
        </group>
        <group group_id="B2">
          <title>Liraglutide 1.2 mg</title>
          <description>Subjects received liraglutide 0.6 mg OD subcutaneously for 2 weeks followed by 1.2 mg OD subcutaneously up to week 52 in addition to their pre-trial insulin treatment.</description>
        </group>
        <group group_id="B3">
          <title>Liraglutide 1.8 mg</title>
          <description>Liraglutide 0.6 mg OD subcutaneously for 2 weeks followed by 1.2 mg OD subcutaneously for 2 weeks (weeks 2-4) followed by 1.8 mg OD subcutaneously up to week 52 in addition to their pre-trial insulin treatment.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Subjects received placebo (matched to liraglutide 0.6, 1.2 and 1.8 mg) OD subcutaneously as an add-on to their pre-trial insulin treatment. Placebo 0.1 mL (placebo matched to liraglutide 0.6 mg): Subjects received 0.1 mL liraglutide placebo for 52 weeks. Placebo 0.2 mL (placebo matched to liraglutide 1.2 mg): Subjects received 0.1 mL for 2 weeks followed by 0.2 mL up to week 52. Placebo 0.3 mL (placebo matched to liraglutide 1.8 mg): Subjects received 0.1 mL for 2 weeks followed by 0.2 mL for next 2 weeks and 0.3 mL up to week 52. All the 3 placebo doses were pooled for data analysis.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="350"/>
            <count group_id="B2" value="346"/>
            <count group_id="B3" value="346"/>
            <count group_id="B4" value="347"/>
            <count group_id="B5" value="1389"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.6" spread="12.78"/>
                    <measurement group_id="B2" value="43.9" spread="13.06"/>
                    <measurement group_id="B3" value="43.7" spread="13.33"/>
                    <measurement group_id="B4" value="43.4" spread="12.57"/>
                    <measurement group_id="B5" value="43.7" spread="12.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                    <measurement group_id="B2" value="179"/>
                    <measurement group_id="B3" value="181"/>
                    <measurement group_id="B4" value="180"/>
                    <measurement group_id="B5" value="726"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="165"/>
                    <measurement group_id="B4" value="167"/>
                    <measurement group_id="B5" value="663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated haemoglobin (HbA1c)</title>
          <units>percentage of glycosylated haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.18" spread="0.738"/>
                    <measurement group_id="B2" value="8.16" spread="0.779"/>
                    <measurement group_id="B3" value="8.14" spread="0.740"/>
                    <measurement group_id="B4" value="8.15" spread="0.728"/>
                    <measurement group_id="B5" value="8.16" spread="0.746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86.54" spread="17.338"/>
                    <measurement group_id="B2" value="85.39" spread="17.210"/>
                    <measurement group_id="B3" value="86.27" spread="17.321"/>
                    <measurement group_id="B4" value="86.41" spread="17.768"/>
                    <measurement group_id="B5" value="86.15" spread="17.397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total daily actual insulin dose-continuous subcutaneous insulin infusion</title>
          <description>Total insulin daily dose of subjects who were on continuous subcutaneous insulin infusion treatment. Number of subjects analysed=69 (liraglutide 0.6 mg), 99 (liraglutide 1.2 mg), 113 (liraglutide 1.8 mg), 95 (Placebo).</description>
          <units>units</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.97" lower_limit="13.8" upper_limit="137.1"/>
                    <measurement group_id="B2" value="50.73" lower_limit="19.7" upper_limit="160.5"/>
                    <measurement group_id="B3" value="50.46" lower_limit="8.7" upper_limit="150.2"/>
                    <measurement group_id="B4" value="49.18" lower_limit="3.9" upper_limit="176.1"/>
                    <measurement group_id="B5" value="50.65" lower_limit="3.9" upper_limit="176.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total daily actual insulin dose - Multiple daily injections</title>
          <description>Total insulin daily dose of subjects who were on multiple daily insulin injection treatment. Number of subjects analysed=277 (liraglutide 0.6 mg), 242 (liraglutide 1.2 mg), 227 (liraglutide 1.8 mg), 250 (Placebo).</description>
          <units>units</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.54" lower_limit="22.9" upper_limit="181.6"/>
                    <measurement group_id="B2" value="59.61" lower_limit="16" upper_limit="282.5"/>
                    <measurement group_id="B3" value="62.52" lower_limit="16.4" upper_limit="271.3"/>
                    <measurement group_id="B4" value="62.42" lower_limit="20.3" upper_limit="230"/>
                    <measurement group_id="B5" value="60.94" lower_limit="16" upper_limit="282.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in HbA1c (Glycosylated Haemoglobin)</title>
        <description>Change from baseline in HbA1c at week 52. Missing values were handled by using a mixed model for repeated measurements (MMRM).</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>Full analysis set. Number of subjects analysed=subjects with any post-baseline HbA1c data.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 0.6 mg</title>
            <description>Subjects received liraglutide 0.6 mg once daily (OD) subcutaneously for 52 weeks in addition to their pre-trial insulin treatment.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide 1.2 mg</title>
            <description>Subjects received liraglutide 0.6 mg OD subcutaneously for 2 weeks followed by 1.2 mg OD subcutaneously up to week 52 in addition to their pre-trial insulin treatment.</description>
          </group>
          <group group_id="O3">
            <title>Liraglutide 1.8 mg</title>
            <description>Liraglutide 0.6 mg OD subcutaneously for 2 weeks followed by 1.2 mg OD subcutaneously for 2 weeks (weeks 2-4) followed by 1.8 mg OD subcutaneously up to week 52 in addition to their pre-trial insulin treatment.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Subjects received placebo (matched to liraglutide 0.6, 1.2 and 1.8 mg) OD subcutaneously as an add-on to their pre-trial insulin treatment. Placebo 0.1 mL (placebo matched to liraglutide 0.6 mg): Subjects received 0.1 mL liraglutide placebo for 52 weeks. Placebo 0.2 mL (placebo matched to liraglutide 1.2 mg): Subjects received 0.1 mL for 2 weeks followed by 0.2 mL up to week 52. Placebo 0.3 mL (placebo matched to liraglutide 1.8 mg): Subjects received 0.1 mL for 2 weeks followed by 0.2 mL for next 2 weeks and 0.3 mL up to week 52. All the 3 placebo doses were pooled for data analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c (Glycosylated Haemoglobin)</title>
          <description>Change from baseline in HbA1c at week 52. Missing values were handled by using a mixed model for repeated measurements (MMRM).</description>
          <population>Full analysis set. Number of subjects analysed=subjects with any post-baseline HbA1c data.</population>
          <units>percentage of glycosylated haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="312"/>
                <count group_id="O3" value="305"/>
                <count group_id="O4" value="324"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.741"/>
                    <measurement group_id="O2" value="-0.50" spread="0.767"/>
                    <measurement group_id="O3" value="-0.54" spread="0.729"/>
                    <measurement group_id="O4" value="-0.34" spread="0.707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using MMRMs where all post-baseline measurements for the specific variable from planned visits up to week 52 and obtained no later than 1 day after withdrawal from treatment were entered as the dependent variable, and visit, treatment, country and the stratification variable (4 levels: HbA1c &lt; 8.5% and â‰¥8.5%, each intersected by BMIâ‰¤27 kg/m2 and &gt;27 kg/m2) were included as fixed factors and the corresponding baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was concluded if the upper bound of 95% confidence interval was &lt;0.3.</non_inferiority_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-0.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.32</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using MMRMs where all post-baseline measurements for the specific variable from planned visits up to week 52 and obtained no later than 1 day after withdrawal from treatment were entered as the dependent variable, and visit, treatment, country and the stratification variable (4 levels: HbA1c &lt; 8.5% and â‰¥8.5%, each intersected by BMIâ‰¤27 kg/m2 and &gt;27 kg/m2) were included as fixed factors and the corresponding baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was concluded if the upper bound of 95% confidence interval was &lt;0.3.</non_inferiority_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.27</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using MMRMs where all post-baseline measurements for the specific variable from planned visits up to week 52 and obtained no later than 1 day after withdrawal from treatment were entered as the dependent variable, and visit, treatment, country and the stratification variable (4 levels: HbA1c &lt; 8.5% and â‰¥8.5%, each intersected by BMIâ‰¤27 kg/m2 and &gt;27 kg/m2) were included as fixed factors and the corresponding baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was concluded if the upper bound of 95% confidence interval was &lt;0.3.</non_inferiority_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Body Weight</title>
        <description>Change from baseline in body weight at week 52. Missing values were handled by using a MMRM.</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>Full analysis set. Number of subjects analysed=subjects with any post-baseline body weight data.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 0.6 mg</title>
            <description>Subjects received liraglutide 0.6 mg once daily (OD) subcutaneously for 52 weeks in addition to their pre-trial insulin treatment.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide 1.2 mg</title>
            <description>Subjects received liraglutide 0.6 mg OD subcutaneously for 2 weeks followed by 1.2 mg OD subcutaneously up to week 52 in addition to their pre-trial insulin treatment.</description>
          </group>
          <group group_id="O3">
            <title>Liraglutide 1.8 mg</title>
            <description>Liraglutide 0.6 mg OD subcutaneously for 2 weeks followed by 1.2 mg OD subcutaneously for 2 weeks (weeks 2-4) followed by 1.8 mg OD subcutaneously up to week 52 in addition to their pre-trial insulin treatment.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Subjects received placebo (matched to liraglutide 0.6, 1.2 and 1.8 mg) OD subcutaneously as an add-on to their pre-trial insulin treatment. Placebo 0.1 mL (placebo matched to liraglutide 0.6 mg): Subjects received 0.1 mL liraglutide placebo for 52 weeks. Placebo 0.2 mL (placebo matched to liraglutide 1.2 mg): Subjects received 0.1 mL for 2 weeks followed by 0.2 mL up to week 52. Placebo 0.3 mL (placebo matched to liraglutide 1.8 mg): Subjects received 0.1 mL for 2 weeks followed by 0.2 mL for next 2 weeks and 0.3 mL up to week 52. All the 3 placebo doses were pooled for data analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight</title>
          <description>Change from baseline in body weight at week 52. Missing values were handled by using a MMRM.</description>
          <population>Full analysis set. Number of subjects analysed=subjects with any post-baseline body weight data.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="300"/>
                <count group_id="O3" value="298"/>
                <count group_id="O4" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="4.183"/>
                    <measurement group_id="O2" value="-2.73" spread="4.524"/>
                    <measurement group_id="O3" value="-4.02" spread="4.873"/>
                    <measurement group_id="O4" value="0.94" spread="3.828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using MMRMs where all post-baseline measurements for the specific variable from planned visits up to week 52 and obtained no later than 1 day after withdrawal from treatment were entered as the dependent variable, and visit, treatment, country and the stratification variable (4 levels: HbA1c &lt; 8.5% and â‰¥8.5%, each intersected by BMIâ‰¤27 kg/m2 and &gt;27 kg/m2) were included as fixed factors and the corresponding baseline value as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Treatment difference</param_type>
            <param_value>-4.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.65</ci_lower_limit>
            <ci_upper_limit>-4.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using MMRMs where all post-baseline measurements for the specific variable from planned visits up to week 52 and obtained no later than 1 day after withdrawal from treatment were entered as the dependent variable, and visit, treatment, country and the stratification variable (4 levels: HbA1c &lt; 8.5% and â‰¥8.5%, each intersected by BMIâ‰¤27 kg/m2 and &gt;27 kg/m2) were included as fixed factors and the corresponding baseline value as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Treatment difference</param_type>
            <param_value>-3.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.29</ci_lower_limit>
            <ci_upper_limit>-2.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using MMRMs where all post-baseline measurements for the specific variable from planned visits up to week 52 and obtained no later than 1 day after withdrawal from treatment were entered as the dependent variable, and visit, treatment, country and the stratification variable (4 levels: HbA1c &lt; 8.5% and â‰¥8.5%, each intersected by BMIâ‰¤27 kg/m2 and &gt;27 kg/m2) were included as fixed factors and the corresponding baseline value as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Treatment difference</param_type>
            <param_value>-2.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.91</ci_lower_limit>
            <ci_upper_limit>-1.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Total Daily Insulin Dose</title>
        <description>Change from baseline in total daily insulin dose at week 52. Change from baseline was represented in terms of ratio to baseline for insulin dose i.e. Total daily insulin dose at week 52/total daily insulin dose at baseline. Missing values were handled by using a MMRM.</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>Full analysis set. Number of subjects analysed=subjects with any post-baseline total insulin daily dose data.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 0.6 mg</title>
            <description>Subjects received liraglutide 0.6 mg once daily (OD) subcutaneously for 52 weeks in addition to their pre-trial insulin treatment.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide 1.2 mg</title>
            <description>Subjects received liraglutide 0.6 mg OD subcutaneously for 2 weeks followed by 1.2 mg OD subcutaneously up to week 52 in addition to their pre-trial insulin treatment.</description>
          </group>
          <group group_id="O3">
            <title>Liraglutide 1.8 mg</title>
            <description>Liraglutide 0.6 mg OD subcutaneously for 2 weeks followed by 1.2 mg OD subcutaneously for 2 weeks (weeks 2-4) followed by 1.8 mg OD subcutaneously up to week 52 in addition to their pre-trial insulin treatment.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Subjects received placebo (matched to liraglutide 0.6, 1.2 and 1.8 mg) OD subcutaneously as an add-on to their pre-trial insulin treatment. Placebo 0.1 mL (placebo matched to liraglutide 0.6 mg): Subjects received 0.1 mL liraglutide placebo for 52 weeks. Placebo 0.2 mL (placebo matched to liraglutide 1.2 mg): Subjects received 0.1 mL for 2 weeks followed by 0.2 mL up to week 52. Placebo 0.3 mL (placebo matched to liraglutide 1.8 mg): Subjects received 0.1 mL for 2 weeks followed by 0.2 mL for next 2 weeks and 0.3 mL up to week 52. All the 3 placebo doses were pooled for data analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Daily Insulin Dose</title>
          <description>Change from baseline in total daily insulin dose at week 52. Change from baseline was represented in terms of ratio to baseline for insulin dose i.e. Total daily insulin dose at week 52/total daily insulin dose at baseline. Missing values were handled by using a MMRM.</description>
          <population>Full analysis set. Number of subjects analysed=subjects with any post-baseline total insulin daily dose data.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="337"/>
                <count group_id="O2" value="328"/>
                <count group_id="O3" value="331"/>
                <count group_id="O4" value="341"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread="23.75"/>
                    <measurement group_id="O2" value="0.98" spread="26.66"/>
                    <measurement group_id="O3" value="0.95" spread="24.21"/>
                    <measurement group_id="O4" value="1.04" spread="26.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis was done using MMRMs where all post-baseline measurements for specific variable from planned visits up to week 52 and obtained no later than 1 day after withdrawal from treatment were entered as dependent variable, and visit, treatment, country and stratification variable (4 levels: HbA1c &lt; 8.5% and â‰¥8.5%, each intersected by BMIâ‰¤27 kg/m2 and &gt;27 kg/m2) were included as fixed factors and the corresponding baseline value as covariate. The measurements were log-transformed before analysis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Treatment ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis was done using MMRMs where all post-baseline measurements for specific variable from planned visits up to week 52 and obtained no later than 1 day after withdrawal from treatment were entered as dependent variable, and visit, treatment, country and stratification variable (4 levels: HbA1c &lt; 8.5% and â‰¥8.5%, each intersected by BMIâ‰¤27 kg/m2 and &gt;27 kg/m2) were included as fixed factors and the corresponding baseline value as covariate. The measurements were log-transformed before analysis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0148</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Treatment ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis was done using MMRMs where all post-baseline measurements for specific variable from planned visits up to week 52 and obtained no later than 1 day after withdrawal from treatment were entered as dependent variable, and visit, treatment, country and stratification variable (4 levels: HbA1c &lt; 8.5% and â‰¥8.5%, each intersected by BMIâ‰¤27 kg/m2 and &gt;27 kg/m2) were included as fixed factors and the corresponding baseline value as covariate. The measurements were log-transformed before analysis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9615</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Treatment ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Treatment-emergent Symptomatic Hypoglycaemic Episodes</title>
        <description>This is a confirmatory secondary endpoint. Symptomatic hypoglycaemic episodes were defined as: 1) Severe according to the American Diabetes Association (ADA) classification: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. OR 2) Self-monitoring of plasma glucose value of &lt;3.1 mmol/L, with symptoms consistent with hypoglycaemia. A treatment emergent episode is defined as an episode with onset date (or increase in severity) on or after first day of exposure to randomised treatment and up to last dose + 7 days.</description>
        <time_frame>Weeks 0-52</time_frame>
        <population>The safety analysis set included all randomised subjects exposed to at least one dose of liraglutide or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 0.6 mg</title>
            <description>Subjects received liraglutide 0.6 mg once daily (OD) subcutaneously for 52 weeks in addition to their pre-trial insulin treatment.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide 1.2 mg</title>
            <description>Subjects received liraglutide 0.6 mg OD subcutaneously for 2 weeks followed by 1.2 mg OD subcutaneously up to week 52 in addition to their pre-trial insulin treatment.</description>
          </group>
          <group group_id="O3">
            <title>Liraglutide 1.8 mg</title>
            <description>Liraglutide 0.6 mg OD subcutaneously for 2 weeks followed by 1.2 mg OD subcutaneously for 2 weeks (weeks 2-4) followed by 1.8 mg OD subcutaneously up to week 52 in addition to their pre-trial insulin treatment.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Subjects received placebo (matched to liraglutide 0.6, 1.2 and 1.8 mg) OD subcutaneously as an add-on to their pre-trial insulin treatment. Placebo 0.1 mL (placebo matched to liraglutide 0.6 mg): Subjects received 0.1 mL liraglutide placebo for 52 weeks. Placebo 0.2 mL (placebo matched to liraglutide 1.2 mg): Subjects received 0.1 mL for 2 weeks followed by 0.2 mL up to week 52. Placebo 0.3 mL (placebo matched to liraglutide 1.8 mg): Subjects received 0.1 mL for 2 weeks followed by 0.2 mL for next 2 weeks and 0.3 mL up to week 52. All the 3 placebo doses were pooled for data analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treatment-emergent Symptomatic Hypoglycaemic Episodes</title>
          <description>This is a confirmatory secondary endpoint. Symptomatic hypoglycaemic episodes were defined as: 1) Severe according to the American Diabetes Association (ADA) classification: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. OR 2) Self-monitoring of plasma glucose value of &lt;3.1 mmol/L, with symptoms consistent with hypoglycaemia. A treatment emergent episode is defined as an episode with onset date (or increase in severity) on or after first day of exposure to randomised treatment and up to last dose + 7 days.</description>
          <population>The safety analysis set included all randomised subjects exposed to at least one dose of liraglutide or placebo.</population>
          <units>episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="350"/>
                <count group_id="O2" value="348"/>
                <count group_id="O3" value="347"/>
                <count group_id="O4" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4954"/>
                    <measurement group_id="O2" value="4602"/>
                    <measurement group_id="O3" value="4614"/>
                    <measurement group_id="O4" value="3654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The endpoint was analysed using a negative binomial regression model with a log-link function and the log of the time period in which an occurrence of a hypoglycaemic episode was considered treatment emergent as offset. The model included fixed factors (treatment, country, stratification group) and a covariate (baseline HbA1c).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0081</p_value>
            <method>Negative binomial regression</method>
            <param_type>Rate ratio</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.07</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The endpoint was analysed using a negative binomial regression model with a log-link function and the log of the time period in which an occurrence of a hypoglycaemic episode was considered treatment emergent as offset. The model included fixed factors (treatment, country, stratification group) and a covariate (baseline HbA1c).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0219</p_value>
            <method>Negative binomial regression</method>
            <param_type>Rate ratio</param_type>
            <param_value>1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>1.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The endpoint was analysed using a negative binomial regression model with a log-link function and the log of the time period in which an occurrence of a hypoglycaemic episode was considered treatment emergent as offset. The model included fixed factors (treatment, country, stratification group) and a covariate (baseline HbA1c).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1079</p_value>
            <method>Negative binomial regression</method>
            <param_type>Rate ratio</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 52 weeks</time_frame>
      <desc>A treatment emergent adverse event is defined as an event with onset date (or increase in severity) on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Liraglutide 0.6 mg</title>
          <description>Subjects received liraglutide 0.6 mg once daily (OD) subcutaneously for 52 weeks in addition to their pre-trial insulin treatment.</description>
        </group>
        <group group_id="E2">
          <title>Liraglutide 1.2 mg</title>
          <description>Subjects received liraglutide 0.6 mg OD subcutaneously for 2 weeks followed by 1.2 mg OD subcutaneously up to week 52 in addition to their pre-trial insulin treatment.</description>
        </group>
        <group group_id="E3">
          <title>Liraglutide 1.8 mg</title>
          <description>Liraglutide 0.6 mg OD subcutaneously for 2 weeks followed by 1.2 mg OD subcutaneously for 2 weeks (weeks 2-4) followed by 1.8 mg OD subcutaneously up to week 52 in addition to their pre-trial insulin treatment.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Subjects received placebo (matched to liraglutide 0.6, 1.2 and 1.8 mg) OD subcutaneously as an add-on to their pre-trial insulin treatment. Placebo 0.1 mL (placebo matched to liraglutide 0.6 mg): Subjects received 0.1 mL liraglutide placebo for 52 weeks. Placebo 0.2 mL (placebo matched to liraglutide 1.2 mg): Subjects received 0.1 mL for 2 weeks followed by 0.2 mL up to week 52. Placebo 0.3 mL (placebo matched to liraglutide 1.8 mg): Subjects received 0.1 mL for 2 weeks followed by 0.2 mL for next 2 weeks and 0.3 mL up to week 52. All the 3 placebo doses were pooled for data analysis.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDra 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="350"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="348"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Melkersson-Rosenthal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Suture related complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Biopsy prostate</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="350"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="348"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="347"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Hyperosmolar hyperglycaemic state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="350"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="348"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="347"/>
                <counts group_id="E4" events="16" subjects_affected="13" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Haemangioma of bone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Invasive lobular breast carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrospinal fluid leakage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic unconsciousness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="350"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="348"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="347"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Tonsillar inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Obesity surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Toe amputation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Popliteal artery entrapment syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDra 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="259" subjects_at_risk="350"/>
                <counts group_id="E2" subjects_affected="263" subjects_at_risk="348"/>
                <counts group_id="E3" subjects_affected="282" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="224" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="32" subjects_affected="20" subjects_at_risk="350"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="348"/>
                <counts group_id="E3" events="41" subjects_affected="29" subjects_at_risk="347"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="350"/>
                <counts group_id="E2" events="30" subjects_affected="28" subjects_at_risk="348"/>
                <counts group_id="E3" events="28" subjects_affected="26" subjects_at_risk="347"/>
                <counts group_id="E4" events="11" subjects_affected="9" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="52" subjects_affected="41" subjects_at_risk="350"/>
                <counts group_id="E2" events="69" subjects_affected="50" subjects_at_risk="348"/>
                <counts group_id="E3" events="92" subjects_affected="64" subjects_at_risk="347"/>
                <counts group_id="E4" events="50" subjects_affected="38" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="26" subjects_at_risk="350"/>
                <counts group_id="E2" events="41" subjects_affected="27" subjects_at_risk="348"/>
                <counts group_id="E3" events="48" subjects_affected="38" subjects_at_risk="347"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="146" subjects_affected="112" subjects_at_risk="350"/>
                <counts group_id="E2" events="196" subjects_affected="141" subjects_at_risk="348"/>
                <counts group_id="E3" events="271" subjects_affected="172" subjects_at_risk="347"/>
                <counts group_id="E4" events="52" subjects_affected="42" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="26" subjects_affected="24" subjects_at_risk="350"/>
                <counts group_id="E2" events="58" subjects_affected="44" subjects_at_risk="348"/>
                <counts group_id="E3" events="106" subjects_affected="64" subjects_at_risk="347"/>
                <counts group_id="E4" events="26" subjects_affected="21" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="350"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="348"/>
                <counts group_id="E3" events="21" subjects_affected="18" subjects_at_risk="347"/>
                <counts group_id="E4" events="18" subjects_affected="16" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="350"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="348"/>
                <counts group_id="E3" events="32" subjects_affected="29" subjects_at_risk="347"/>
                <counts group_id="E4" events="21" subjects_affected="15" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="350"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="348"/>
                <counts group_id="E3" events="24" subjects_affected="18" subjects_at_risk="347"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="32" subjects_affected="29" subjects_at_risk="350"/>
                <counts group_id="E2" events="26" subjects_affected="17" subjects_at_risk="348"/>
                <counts group_id="E3" events="28" subjects_affected="25" subjects_at_risk="347"/>
                <counts group_id="E4" events="30" subjects_affected="24" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="175" subjects_affected="105" subjects_at_risk="350"/>
                <counts group_id="E2" events="124" subjects_affected="81" subjects_at_risk="348"/>
                <counts group_id="E3" events="145" subjects_affected="83" subjects_at_risk="347"/>
                <counts group_id="E4" events="130" subjects_affected="85" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="35" subjects_affected="24" subjects_at_risk="350"/>
                <counts group_id="E2" events="22" subjects_affected="17" subjects_at_risk="348"/>
                <counts group_id="E3" events="21" subjects_affected="16" subjects_at_risk="347"/>
                <counts group_id="E4" events="31" subjects_affected="21" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="37" subjects_affected="33" subjects_at_risk="350"/>
                <counts group_id="E2" events="37" subjects_affected="23" subjects_at_risk="348"/>
                <counts group_id="E3" events="59" subjects_affected="43" subjects_at_risk="347"/>
                <counts group_id="E4" events="58" subjects_affected="40" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="28" subjects_affected="18" subjects_at_risk="350"/>
                <counts group_id="E2" events="21" subjects_affected="14" subjects_at_risk="348"/>
                <counts group_id="E3" events="26" subjects_affected="20" subjects_at_risk="347"/>
                <counts group_id="E4" events="15" subjects_affected="11" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="32" subjects_affected="31" subjects_at_risk="350"/>
                <counts group_id="E2" events="45" subjects_affected="43" subjects_at_risk="348"/>
                <counts group_id="E3" events="70" subjects_affected="64" subjects_at_risk="347"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="17" subjects_at_risk="350"/>
                <counts group_id="E2" events="26" subjects_affected="17" subjects_at_risk="348"/>
                <counts group_id="E3" events="38" subjects_affected="22" subjects_at_risk="347"/>
                <counts group_id="E4" events="28" subjects_affected="17" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="32" subjects_affected="26" subjects_at_risk="350"/>
                <counts group_id="E2" events="18" subjects_affected="13" subjects_at_risk="348"/>
                <counts group_id="E3" events="37" subjects_affected="20" subjects_at_risk="347"/>
                <counts group_id="E4" events="35" subjects_affected="24" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="350"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="348"/>
                <counts group_id="E3" events="19" subjects_affected="18" subjects_at_risk="347"/>
                <counts group_id="E4" events="16" subjects_affected="16" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="78" subjects_affected="56" subjects_at_risk="350"/>
                <counts group_id="E2" events="85" subjects_affected="46" subjects_at_risk="348"/>
                <counts group_id="E3" events="119" subjects_affected="49" subjects_at_risk="347"/>
                <counts group_id="E4" events="77" subjects_affected="40" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="350"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="348"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="347"/>
                <counts group_id="E4" events="24" subjects_affected="21" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="350"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="348"/>
                <counts group_id="E3" events="32" subjects_affected="28" subjects_at_risk="347"/>
                <counts group_id="E4" events="15" subjects_affected="13" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Novo Nordisk commits to communicating, and otherwise making available for public disclosure, results of trials regardless of outcome.At the end of the trial, one or more public disclosures may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Public Access to Clinical Trials</name_or_title>
      <organization>Novo Nordisk A/S</organization>
      <email>clinicaltrials@novonordisk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

